Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Ophthalmology

Is Your Normal Tension Glaucoma Actually ADOA?

At a Glance

Autosomal Dominant Optic Atrophy (ADOA) is sometimes misdiagnosed as normal tension glaucoma because both cause vision loss without high eye pressure. However, ADOA typically starts in childhood, affects central and color vision, and can be definitively diagnosed with OPA1 genetic testing.

Yes, it is entirely possible for Autosomal Dominant Optic Atrophy (ADOA) to be misdiagnosed as normal tension glaucoma (NTG) [1][2]. Both conditions involve damage to the optic nerve that leads to progressive vision loss, and importantly, both occur without the high fluid pressure in the eye that is typical of standard glaucoma. Because of these similarities, some patients with ADOA receive an incorrect diagnosis of NTG and may even be prescribed glaucoma treatments that will not help their underlying condition [1]. (Important: Never stop taking prescribed glaucoma eye drops without consulting your doctor, as doing so can be dangerous if your glaucoma diagnosis is correct.)

However, specialized eye exams, family history, and genetic testing can clearly distinguish between the two diseases.

How the Symptoms Differ

While both conditions cause vision loss, how you lose your vision can be a major clue:

  • Central vs. Peripheral Vision: ADOA typically affects your central vision first, making it difficult to read or see faces clearly. NTG, like most forms of glaucoma, usually begins by damaging your peripheral (side) vision.
  • Color Vision: People with ADOA frequently develop color vision issues early on, particularly struggling to distinguish between blues and yellows. NTG rarely affects color vision in its early stages.

Distinct Patterns on OCT Scans

Eye doctors use a non-invasive imaging test called Optical Coherence Tomography (OCT) to measure the thickness of different layers in the back of your eye. While both ADOA and NTG cause thinning in these layers, the specific patterns of damage are distinct:

  • GCC and RNFL Thinning: Both conditions cause tissue loss in the Retinal Nerve Fiber Layer (RNFL) and the Ganglion Cell Complex (GCC), which are crucial bundles of nerve fibers and cells that send visual signals to the brain. However, the pattern of this thinning is uniquely different [3][4]. In ADOA, the thinning usually happens on the temporal side of the nerve (the outer side, towards your ear) and involves the central macula [5][6]. In NTG, the thinning typically occurs at the superior (top) and inferior (bottom) edges of the nerve.
  • Optic Disc Appearance: When the doctor examines the optic nerve head (the optic disc), NTG typically causes cupping (a hollowed-out appearance where nerve tissue has been lost), whereas ADOA generally causes pallor (a pale appearance due to dying nerve fibers losing their healthy color) [7][1].
  • Lamina Cribrosa Shape: The lamina cribrosa is a mesh-like structure in the back of the eye where the optic nerve fibers exit toward the brain. In NTG, this structure is typically deeper and curved further backward than it is in a healthy eye or an eye with ADOA [8].

Age of Onset and Family History

The timeline and family history of your vision changes are often the biggest clues that point away from glaucoma and toward ADOA:

  • Age of Onset: Normal tension glaucoma is predominantly a disease of older adulthood. In contrast, ADOA usually begins causing visual changes in early childhood, even if the formal diagnosis is delayed for years [9]. Finding distinct patterns of nerve layer thinning in a young patient is a strong clinical clue for ADOA rather than NTG [3].
  • Family History: Because ADOA is an inherited genetic condition, there is very often a family history of unexplained vision loss or “blindness” in parents, siblings, or grandparents [10][2]. NTG does not usually follow this same predictable family inheritance pattern.

Confirming the Diagnosis with Genetic Testing

While OCT scans and family history provide strong clues, the definitive way to tell ADOA apart from NTG is through genetic testing. Identifying a mutation in the OPA1 gene—the gene responsible for the vast majority of ADOA cases—will confirm a diagnosis of dominant optic atrophy [11][12].

If you or your doctor suspect your NTG diagnosis might be incorrect based on your symptoms or scans, requesting a genetic test or a referral to a neuro-ophthalmologist is the most direct path to getting an accurate answer [13]. Getting the correct diagnosis means you can stop ineffective pressure-lowering drops (under a doctor’s supervision) and instead focus on appropriate genetic counseling, low-vision support, and specialized monitoring tailored for ADOA.

Common questions in this guide

Why is ADOA commonly misdiagnosed as normal tension glaucoma?
Both conditions cause optic nerve damage and progressive vision loss without elevated fluid pressure in the eye. Because normal tension glaucoma is more widely known, doctors may initially mistake the signs of ADOA for glaucoma if specialized imaging or genetic testing is not performed.
How can an eye doctor tell the difference between ADOA and glaucoma?
Eye doctors use Optical Coherence Tomography (OCT) scans to examine patterns of nerve damage. ADOA usually causes nerve thinning on the temporal side and optic disc pallor, whereas normal tension glaucoma typically causes thinning at the top and bottom edges along with optic disc cupping.
What are the early symptoms of Autosomal Dominant Optic Atrophy?
ADOA typically starts in early childhood with a gradual loss of central vision, making it hard to read or see faces clearly. Many patients also experience early color vision issues, particularly struggling to distinguish between blues and yellows.
Can genetic testing prove I have ADOA instead of glaucoma?
Yes, genetic testing is the definitive way to confirm Autosomal Dominant Optic Atrophy. Finding a mutation in the OPA1 gene, which causes the vast majority of ADOA cases, will clearly differentiate it from normal tension glaucoma.
Should I stop taking my glaucoma eye drops if I think I have ADOA?
No, you should never stop taking prescribed glaucoma eye drops without consulting your eye doctor. If you suspect an ADOA misdiagnosis, discuss your concerns with a neuro-ophthalmologist so they can confirm the correct diagnosis and help you safely transition off the drops.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can we re-review my past OCT scans specifically looking for temporal thinning and optic disc pallor rather than the cupping typical of glaucoma?
  2. 2.Given my age when my vision problems first started and my family history, do you recommend I see a neuro-ophthalmologist?
  3. 3.Does the structural shape of my optic nerve—specifically the lamina cribrosa—look deep and curved like typical glaucoma, or does it look more aligned with a different optic neuropathy?
  4. 4.Should we consider ordering an OPA1 genetic test to definitively rule out Autosomal Dominant Optic Atrophy?
  5. 5.If my condition turns out to be ADOA instead of normal tension glaucoma, how would we safely transition me off my current glaucoma eye drops?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    [Differential diagnosis of juvenile normal pressure glaucoma].

    Geidel K, Wiedemann P, Unterlauft JD

    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2017; (114(9)):828-831 doi:10.1007/s00347-016-0407-5.

    PMID: 27921132
  2. 2

    ATPase Domain AFG3L2 Mutations Alter OPA1 Processing and Cause Optic Neuropathy.

    Caporali L, Magri S, Legati A, et al.

    Annals of neurology 2020; (88(1)):18-32 doi:10.1002/ana.25723.

    PMID: 32219868
  3. 3

    Comparison of the clinical and genetic features of autosomal dominant optic atrophy and normal tension glaucoma in young Chinese adults.

    Zhang Y, Sun X, Tian G, Chen Y

    Eye (London, England) 2023; (37(4)):624-630 doi:10.1038/s41433-022-01990-y.

    PMID: 35273349
  4. 4

    Clinical and Structural Parameters in Autosomal Dominant Optic Atrophy Patients: A Cross-Sectional Study Using Optical Coherence Tomography.

    Camós-Carreras A, Figueras-Roca M, Albà-Arbalat S, et al.

    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2024; (45(3)):273-277 doi:10.1097/WNO.0000000000002294.

    PMID: 39805076
  5. 5

    Assessment of the retinal posterior pole in dominant optic atrophy by spectral-domain optical coherence tomography and microperimetry.

    Cesareo M, Ciuffoletti E, Martucci A, et al.

    PloS one 2017; (12(3)):e0174560 doi:10.1371/journal.pone.0174560.

    PMID: 28358911
  6. 6

    Temporal Raphe Sign for Discrimination of Glaucoma from Optic Neuropathy in Eyes with Macular Ganglion Cell-Inner Plexiform Layer Thinning.

    Lee J, Kim YK, Ha A, et al.

    Ophthalmology 2019; (126(8)):1131-1139 doi:10.1016/j.ophtha.2018.12.031.

    PMID: 30576683
  7. 7

    Incidence of non-glaucomatous ocular disease in patients with asymmetric optic disc cupping.

    Bialer OY, Mimouni M, Dotan G, et al.

    International ophthalmology 2021; (41(8)):2797-2804 doi:10.1007/s10792-021-01836-8.

    PMID: 33821387
  8. 8

    Comparison of Lamina Cribrosa Morphology in Normal Tension Glaucoma and Autosomal-Dominant Optic Atrophy.

    Kim GN, Kim JA, Kim MJ, et al.

    Investigative ophthalmology & visual science 2020; (61(5)):9 doi:10.1167/iovs.61.5.9.

    PMID: 32392317
  9. 9

    A novel AFG3L2 mutation close to AAA domain leads to aberrant OMA1 and OPA1 processing in a family with optic atrophy.

    Baderna V, Schultz J, Kearns LS, et al.

    Acta neuropathologica communications 2020; (8(1)):93 doi:10.1186/s40478-020-00975-w.

    PMID: 32600459
  10. 10

    Genomics combined with a protein informatics platform to assess a novel pathogenic variant c.1024 A>G (p.K342E) in OPA1 in a patient with autosomal dominant optic atrophy.

    Ahuja AS, Selvam P, Vadlamudi C, et al.

    Ophthalmic genetics 2020; (41(6)):563-569 doi:10.1080/13816810.2020.1814344.

    PMID: 32940104
  11. 11

    Exome sequencing identified a novel de novo OPA1 mutation in a consanguineous family presenting with optic atrophy.

    Cohen L, Tzur S, Goldenberg-Cohen N, et al.

    Genetics research 2016; (98()):e10 doi:10.1017/S0016672316000070.

    PMID: 27265430
  12. 12

    Mutation spectrum of the OPA1 gene in a large cohort of patients with suspected dominant optic atrophy: Identification and classification of 48 novel variants.

    Weisschuh N, Schimpf-Linzenbold S, Mazzola P, et al.

    PloS one 2021; (16(7)):e0253987 doi:10.1371/journal.pone.0253987.

    PMID: 34242285
  13. 13

    Molecular Impairment Mechanisms of Novel OPA1 Mutations Predicted by Molecular Modeling in Patients With Autosomal Dominant Optic Atrophy and Auditory Neuropathy Spectrum Disorder.

    Namba K, Mutai H, Takiguchi Y, et al.

    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2016; (37(4)):394-402 doi:10.1097/MAO.0000000000000978.

    PMID: 26905822

This page is for informational purposes only and does not replace professional medical advice. Never stop taking prescribed glaucoma medications without first consulting your eye doctor.

Get notified when new evidence is published on Autosomal dominant optic atrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.